Stockreport

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer [Yahoo! Finance]

Genmab A/S - American Depositary Shares  (GMAB) 
PDF objective response rate (ORR) of 55.6% and median duration of response (mDOR) was not reached Phase 2 RAINFOL TM -01 and Phase 3 RAINFOL TM -02 trials evaluating the s [Read more]